Henry Schein’s (HSIC) Buy Rating Reaffirmed at BTIG Research

Henry Schein (NASDAQ:HSIC)‘s stock had its “buy” rating restated by equities researchers at BTIG Research in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $100.00 target price on the stock. BTIG Research’s price target indicates a potential upside of 12.22% from the stock’s previous close.

Several other research analysts have also recently issued reports on the stock. Mizuho reduced their target price on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Robert W. Baird set a $97.00 price target on shares of Henry Schein in a report on Wednesday, May 6th. Piper Sandler increased their price target on Henry Schein from $91.00 to $95.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Citigroup assumed coverage on Henry Schein in a research note on Wednesday, April 15th. They set a “buy” rating and a $100.00 price objective for the company. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Henry Schein in a report on Friday. Eight equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $89.36.

Henry Schein Price Performance

Shares of NASDAQ HSIC opened at $89.11 on Wednesday. Henry Schein has a 52 week low of $61.94 and a 52 week high of $92.18. The business’s 50 day moving average price is $82.74 and its 200 day moving average price is $78.47. The company has a quick ratio of 0.75, a current ratio of 1.36 and a debt-to-equity ratio of 0.59. The firm has a market cap of $10.15 billion, a P/E ratio of 26.92, a P/E/G ratio of 1.66 and a beta of 0.80.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $1.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.24 by $0.03. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The company had revenue of $3.46 billion during the quarter, compared to analyst estimates of $3.37 billion. During the same period last year, the firm posted $1.10 EPS. Henry Schein’s revenue for the quarter was up 6.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. On average, sell-side analysts expect that Henry Schein will post 5.32 earnings per share for the current year.

Insider Activity

In other news, Director William K. Daniel acquired 10,000 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was acquired at an average price of $69.19 per share, for a total transaction of $691,900.00. Following the completion of the transaction, the director owned 20,000 shares in the company, valued at approximately $1,383,800. The trade was a 100.00% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.89% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Henry Schein

Institutional investors and hedge funds have recently modified their holdings of the business. Ameriprise Financial Inc. raised its holdings in Henry Schein by 3,275.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock worth $165,594,000 after purchasing an additional 2,199,695 shares during the period. Bank of Montreal Can grew its holdings in Henry Schein by 3,655.7% in the fourth quarter. Bank of Montreal Can now owns 2,144,773 shares of the company’s stock valued at $162,102,000 after purchasing an additional 2,087,666 shares during the period. Norges Bank acquired a new stake in Henry Schein in the fourth quarter valued at approximately $88,116,000. Southpoint Capital Advisors LP increased its position in shares of Henry Schein by 28.0% in the first quarter. Southpoint Capital Advisors LP now owns 3,200,000 shares of the company’s stock valued at $235,840,000 after buying an additional 700,000 shares in the last quarter. Finally, Bank of America Corp DE increased its position in shares of Henry Schein by 204.2% in the second quarter. Bank of America Corp DE now owns 995,375 shares of the company’s stock valued at $72,712,000 after buying an additional 668,182 shares in the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Key Headlines Impacting Henry Schein

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Quarterly results exceeded expectations: Henry Schein reported adjusted EPS of $1.27, above the $1.24 consensus estimate, while revenue reached $3.46 billion versus expectations of approximately $3.37 billion. Revenue increased 6.7% year over year, and EPS rose from $1.10 in the prior-year quarter. HSIC Surpasses Q2 Earnings and Revenue Estimates, Stock Climbs
• Positive Sentiment: Management raised fiscal 2026 guidance: The company now expects adjusted EPS of $5.29 to $5.39 and revenue of $13.8 billion to $13.9 billion. The revenue outlook implies 4.5% to 5.5% growth, while adjusted EBITDA is projected to increase at a mid- to high-single-digit rate. The revenue range is above the roughly $13.7 billion analyst consensus. Henry Schein Reports Strong Second Quarter 2026 Financial Results and Raises FY2026 Guidance
• Positive Sentiment: Growth was broad based: Global Distribution and Value-Added Services sales rose 6.6%, Specialty Products increased 8.7% and Technology sales grew 8.2%. Henry Schein also repurchased approximately 2.6 million shares for $200 million during the quarter, supporting per-share results. Henry Schein 2026 Q2 Results Earnings Call Presentation
• Negative Sentiment: Insider selling remains a potential overhang: Recent reporting showed six insider sales and no insider purchases over the past six months, including sales by senior executives. This may temper investor enthusiasm, although it is less significant than the company’s current earnings and guidance upgrades. Henry Schein Q2 Revenue Rises 6.7%

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.